Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH4 for Muscle Dysfunction in COPD
NCT04014712Phase 1Withdrawn
- Sponsor
- University of Massachusetts Amherst
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sapropterin in chronic obstructive pulmonary disease (COPD), sponsored by University of Massachusetts Amherst. Primary endpoints: Mitochondrial function at 4 hours and intracellular PO2 at 4 hours. Planned start Apr 2021; status: withdrawn.
02
Drugs
sapropterin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04014712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014712.